Worth reading
65In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
1359
¥ million (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationFiscal year ending March 202611 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥41,899 million+3.4%
Operating profit¥2,919 million-2.7%
Ordinary income¥2,844 million-11.1%
Net income¥3,708 million+66.5%
Selling, general and administrative expenses¥13,255 million
Gross Profit Margin38.6% (year-on-year change in percentage points: Not disclosed)
Operating profit margin7.0% (year-on-year change in percentage points: Not disclosed)
Full-year earnings forecast
Fiscal Period CoveredFiscal year ending March 2027
Net Sales
¥42,000 million
Cost of sales
¥25,650 million
Gross profit
¥16,350 million
Selling, general and administrative expenses
¥13,280 million
Operating profit
¥3,070 million
Ordinary income
¥2,900 million
Net income for the current fiscal year
¥2,070 million
Research and development costs
¥3,600 million
Capital Expenditure
¥2,318 million
Depreciation and amortization
¥2,654 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Actual results for the fiscal year ending March 2026
Net Sales99.3%
Cost of sales102.3%
Gross profit94.9%
Selling, general and administrative expenses96.1%
Operating profit89.8%
Ordinary income91.7%
Net income for the current fiscal year98.4%
By segment
Fecal occult blood testing98.8%
Immunoserology (excluding fecal occult blood)101.4%
Urine testing97.5%
Microbiology87.4%
Biochemistry94.9%
Instruments, food and environmental testing97.7%
Genetic testing80.2%
Medical equipment and other123.5%
Regional breakdown
Domestic101.0%
Overseas expansion95.1%
Americas99.4%
EMEA90.8%
APAC97.8%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Below forecast / 99.3% of budget, broadly in lineBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue: Japan +¥612 million, the Americas +¥86 million, EMEA +¥491 million, APAC +¥168 million. By segment: fecal occult blood +¥529 million, immunoserology (excluding fecal occult blood) +¥217 million, urinalysis +¥2 million, biochemistry +¥6 million, medical devices and other +¥986 million, microbiology -¥217 million, instruments, food and environmental testing -¥141 million, genetics-related -¥23 million.
New initiatives
- Reformulation of the previous plan as Management Plan 2030
- Rigorous implementation of ROIC-based management
- Alliance with a company strong in the clinic market
- Strengthening strategic partnerships with overseas distributors
- Integration, consolidation and efficiency improvements at production sites
- Expansion of the production engineering structure through process improvements and automation
- Establishment of a structure to promote growth investments and M&A
- Targeted launch of the OC Sensor R70 fecal occult blood analyzer
- Collaboration with Unko Drill, a children's educational series, to promote colorectal cancer screening awareness
Key KPIsA metric the company considers important as a management benchmark.
- Overseas revenue ratio27.3 %
- Countries using FIT56 countries
- Overseas FIT revenue¥69 million
- Number of countries where products are marketed10 countries
- Number of countries where colorectal cancer screening tests are marketed56 countries
Segment results
Fecal occult blood testing
Net Sales
¥13,470 million
Year on year against the same period last year+4.1%
Immunoserology (excluding fecal occult blood)
Net Sales
¥9,816 million
Year on year against the same period last year+2.3%
Urine testing
Net Sales
¥4,623 million
Year on year against the same period last year+0.1%
Microbiology
Net Sales
¥4,284 million
Year on year against the same period last year-4.8%
Biochemistry
Net Sales
¥579 million
Year on year against the same period last year+1.1%
Instruments, food and environmental testing
Net Sales
¥1,818 million
Year on year against the same period last year-7.2%
Genetic testing
Net Sales
¥1,957 million
Year on year against the same period last year-1.2%
Medical equipment and other
Net Sales
¥5,348 million
Year on year against the same period last year+22.6%
Medium-term management plan targets
Plan nameManagement Plan 2030
Target fiscal yearFY2030 (fiscal year ending March 2031)
Net Sales¥50 billion or more (excluding new businesses and non-continuous growth)
Overseas revenue ratio35% or more
Operating profit¥7 billion or more
Operating profit margin14% or higher
ROE10% or higher
ROIC10% or higher
Financial targets
FY2030
ROE10% or higher
ROIC10% or higher
Equity ratioAround 70% or lower
Capital expenditures
3,817 Millions of yen fiscal year ended March 2026 actual
Annual Dividend
Annual dividend per share¥58
Payout ratio
Total payout ratio of around 50% or moreAcquisition of treasury shares
Acquisition amount¥1,675 million (actual share repurchases)
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | ¥41,899 million (YoY +3.4%) |
| Operating profit | ¥2,919 million (YoY -2.7%) |
| Ordinary income | ¥2,844 million (YoY -11.1%) |
| Net income | ¥3,708 million (YoY +66.5%) |
| Gross Profit Margin | 38.6% (year-on-year change in percentage points: Not disclosed) |
| Operating profit margin | 7.0% (year-on-year change in percentage points: Not disclosed) |
| Selling, general and administrative expenses | ¥13,255 million |
| Full-year earnings forecast | Fiscal Period Covered Fiscal year ending March 2027 / Net Sales ¥42,000 million / Cost of sales ¥25,650 million / Gross profit ¥16,350 million / Selling, general and administrative expenses ¥13,280 million / Operating profit ¥3,070 million / Ordinary income ¥2,900 million / Net income for the current fiscal year ¥2,070 million / Research and development costs ¥3,600 million / Capital Expenditure ¥2,318 million / Depreciation and amortization ¥2,654 million |
| Progress against full-year forecast | Actual results for the fiscal year ending March 2026 Net Sales 99.3% / Cost of sales 102.3% / Gross profit 94.9% / Selling, general and administrative expenses 96.1% / Operating profit 89.8% / Ordinary income 91.7% / Net income for the current fiscal year 98.4% / By segment Fecal occult blood testing 98.8% / Immunoserology (excluding fecal occult blood) 101.4% / Urine testing 97.5% / Microbiology 87.4% / Biochemistry 94.9% / Instruments, food and environmental testing 97.7% / Genetic testing 80.2% / Medical equipment and other 123.5% / Regional breakdown Domestic 101.0% / Overseas expansion 95.1% / Americas 99.4% / EMEA 90.8% / APAC 97.8% |
| Self-assessment against the plan | Below forecast / 99.3% of budget, broadly in line |
| Segment results | Fecal occult blood testing Net Sales ¥13,470 million / yoy_pct 4.1 / Immunoserology (excluding fecal occult blood) Net Sales ¥9,816 million / yoy_pct 2.3 / Urine testing Net Sales ¥4,623 million / yoy_pct 0.1 / Microbiology Net Sales ¥4,284 million / yoy_pct -4.8 / Biochemistry Net Sales ¥579 million / yoy_pct 1.1 / Instruments, food and environmental testing Net Sales ¥1,818 million / yoy_pct -7.2 / Genetic testing Net Sales ¥1,957 million / yoy_pct -1.2 / Medical equipment and other Net Sales ¥5,348 million / yoy_pct 22.6 |
| Breakdown of Factors Affecting the Change | Revenue: Japan +¥612 million, the Americas +¥86 million, EMEA +¥491 million, APAC +¥168 million. By segment: fecal occult blood +¥529 million, immunoserology (excluding fecal occult blood) +¥217 million, urinalysis +¥2 million, biochemistry +¥6 million, medical devices and other +¥986 million, microbiology -¥217 million, instruments, food and environmental testing -¥141 million, genetics-related -¥23 million. |
| Key KPIs | Overseas revenue ratio 27.3 %, Countries using FIT 56 countries, Overseas FIT revenue ¥69 million, Number of countries where products are marketed 10 countries, Number of countries where colorectal cancer screening tests are marketed 56 countries |
| Medium-term management plan targets | Plan name Management Plan 2030 / Target fiscal year FY2030 (fiscal year ending March 2031) / Net Sales ¥50 billion or more (excluding new businesses and non-continuous growth) / Overseas revenue ratio 35% or more / Operating profit ¥7 billion or more / Operating profit margin 14% or higher / ROE 10% or higher / ROIC 10% or higher |
| Financial targets | FY2030 ROE 10% or higher / ROIC 10% or higher / Equity ratio Around 70% or lower |
| Annual Dividend | Annual dividend per share ¥58 / Interim and Year-End Breakdown Not disclosed |
| Payout ratio | Total payout ratio of around 50% or more |
| Acquisition of treasury shares | Acquisition amount ¥1,675 million (actual share repurchases) / Number of shares under the buyback program Not disclosed / Period Not disclosed |
| Capital expenditures | 3,817 Millions of yen (fiscal year ended March 2026 actual) |
| New initiatives | Reformulation of the previous plan as Management Plan 2030, Rigorous implementation of ROIC-based management, Alliance with a company strong in the clinic market, Strengthening strategic partnerships with overseas distributors, Integration, consolidation and efficiency improvements at production sites, Expansion of the production engineering structure through process improvements and automation, Establishment of a structure to promote growth investments and M&A, Targeted launch of the OC Sensor R70 fecal occult blood analyzer, Collaboration with Unko Drill, a children's educational series, to promote colorectal cancer screening awareness |
Items this document does not state (9)
Results for the three months of the current quarterUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased mainly due to growth in fecal occult blood testing reagents and medical devices for overseas markets. On the earnings side, operating profit declined as the sales mix changed, while net income increased because the company recorded approximately ¥2 billion in gains on the transfer of interests in a consolidated subsidiary in the second quarter. Factors behind the shortfall against the full-year forecast included the higher cost-of-sales ratio, delays in the effects of measures to strengthen earnings capacity, and negative impacts on the genetics-related and instrument-related businesses following the abolition of USAID.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.